Corporate disclosures
This article was originally published in The Gray Sheet
Executive Summary
Device and drug makers in the U.S. and Europe need to increase information disclosure in order to meet full investor and analyst demands, according to a recent survey by PricewaterhouseCoopers. Entitled "A New Rx for Corporate Disclosure," the report highlights strategic alliance disclosure as particularly deficient. Perception that investor communication is lacking "could have a very direct bearing on the company's success," PricewaterhouseCoopers says...